Reaction
C3 Glomerulopathy reporting signals
As of the last recalculation, C3 Glomerulopathy appears in 199 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 121.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 48 | 121.4 | 121.6 |
| Mycophenolic Acid | 24 | 89.0 | 89.1 |
| Mycophenilic Acid | 16 | 87.7 | 87.8 |
| Ravulizumab | 4 | 31.6 | 31.6 |